# Correction: TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach

**Authors:** Tayebeh Cheraghi-shavi, Razieh Jalal, Zarrin Minuchehr, Frouzandeh Mahjoubi

PMC · DOI: 10.1371/journal.pone.0322319 · PLOS One · 2025-04-04

## Full-text entities

- **Genes:** HMGA2 (high mobility group AT-hook 2) [NCBI Gene 8091] {aka BABL, HMGI-C, HMGIC, LIPO, SRS5, STQTL9}, FXYD3 (FXYD domain containing ion transport regulator 3) [NCBI Gene 5349] {aka MAT8, PLML}, TGM2 (transglutaminase 2) [NCBI Gene 7052] {aka G(h), TG(C), TGC, hTG2, tTG}, LGALS4 (galectin 4) [NCBI Gene 3960] {aka GAL4, L36LBP}
- **Diseases:** colorectal cancer (MESH:D015179)
- **Chemicals:** oxaliplatin (MESH:D000077150)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11970629/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC11970629/full.md

---
Source: https://tomesphere.com/paper/PMC11970629